This blog post explores the principles and potential of how microfluidic devices can overcome the limitations in cancer research and anticancer drug development.
Microfluidic Device
In 2021, 82,688 people died from cancer in South Korea, solidifying cancer’s position as one of the leading causes of death. Cancer mortality rates have been increasing annually, and the importance of cancer diagnosis and treatment continues to grow. Despite improvements in cancer patient survival rates, developing effective anticancer drugs remains a major challenge. Conventional anticancer drug research primarily involved culturing cancer cells on two-dimensional glass surfaces to test drug efficacy. However, this experimental method differs significantly from the biological environment, making it difficult to accurately predict the actual effects of drugs.
Microfluidic devices represent an innovative solution to this problem. A type of ‘Lab on a Chip’, these devices literally implement a laboratory within a small chip. Measuring approximately 3cm in width and height, they utilize micro- and nano-technology to integrate various experimental components. A micrometer (μm) is one millionth of a meter, while a nanometer (nm) is a unit 1000 times smaller than that. Considering that a human hair is about 100μm thick, one can appreciate how small microfluidic devices are. These devices are primarily used for cell experiments, particularly cancer cell culture and testing the efficacy of anticancer drugs.
Structure and Principle
The structure of a microfluidic device consists of channels and pathways designed for cell experiments. They are primarily fabricated using PDMS (Polydimethylsiloxane), a transparent, soft, rubber-like material. The device is completed by imprinting patterns onto the rubber and punching holes. This fabrication method is called soft lithography, similar to molding shapes using plaster molds. Devices made this way offer the advantage of culturing cells in a three-dimensional environment. Unlike traditional experiments conducted on two-dimensional glass, they mimic three-dimensional structures, enabling experiments under conditions similar to the in vivo environment.
For example, cancer cells grow by drawing in surrounding blood vessels to obtain nutrients. Microfluidic devices can experimentally recreate this environment. By moving fluids through channels, conditions similar to actual in-body fluid flow can be created, allowing for more accurate observation of how cancer cells respond.
Expanding Application Fields
Microfluidic devices are applicable not only to cancer research but also to various other fields. For instance, in diagnostic technology, these devices enable rapid and accurate diagnosis by performing diverse tests using extremely small blood samples. They also play a crucial role in drug development and toxicity testing. Specifically, they are used to test the efficacy of new drug candidates and offer the potential to replace traditional animal testing. This technology allows drugs to be tested under conditions more closely mimicking the human cellular environment, overcoming the limitations of animal testing and offering the advantages of saving both cost and time.
Next-Generation Research Trends
Research on microfluidic devices is currently expanding in various aspects. First, active research is underway on designing device structures with greater precision to ensure smooth fluid movement and maintain the robustness of thin channels at the μm and nm scale. Additionally, efforts are being made to simplify device fabrication methods and usage to enable easy operation by non-specialists. As a next-generation diagnostic tool, this device holds significant potential for widespread adoption in applications like cancer diagnosis using small blood samples or measuring red and white blood cell counts.
Furthermore, improving the bonding method between PDMS and glass—a key existing limitation—remains a critical challenge. The difficulty in separating PDMS and glass once bonded has made it hard to extract and observe cultured cells within the device under a microscope. To address this, efforts are underway to improve the bonding method or develop reusable devices.
Future Outlook
Microfluidic devices are currently evolving through convergence not only with biotechnology but also with various scientific and engineering fields. Particularly, the integration of precision machining techniques from mechanical engineering is enhancing device performance and evolving them into systems that provide better data accuracy. This has significantly improved the accuracy of cell experiments and enabled the implementation of diverse bio-mimetic environments. This holds great potential to drive innovation not only in new drug development but also in disease diagnosis, personalized treatment, and a wide range of other fields.
Microfluidic technology is also contributing to the development of new-dimension research and diagnostic tools through convergence with electronics and nanotechnology. For instance, it is advancing by utilizing nanotechnology to fabricate smaller channels and integrating electronic engineering techniques to increase data processing speed and accuracy. These technologies, applied to portable diagnostic devices or real-time monitoring systems, are expected to transform the future healthcare paradigm.
Furthermore, it can play a crucial role in health management and disease prevention for an aging society. Early diagnosis technologies using microfluidic devices can significantly contribute to the early detection and treatment of chronic diseases and cancers, which are increasing in the elderly population. They enable accurate diagnosis using only small amounts of bodily fluid, reducing healthcare costs and providing accessible diagnostic tools to more patients.
Consequently, microfluidic devices are expected to become a major growth engine for the bioindustry. Rapidly advancing across diverse fields, this technology is poised to become a core element in cancer research, new drug development, personalized medicine, and next-generation healthcare systems.
